SAN FRANCISCO–(BUSINESS WIRE)–The US Food and Drug Administration has approved the use of iTFlow® in blood flow analysis. The FDA approval is significant as it recognizes the safety and effectiveness of iTFlow® in analyzing blood flow through 4D Flow MRI data, with the potential to enhance diagnostic accuracy for patients […]
Coronary/Structural Heart
Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
Ghent, Belgium – 16 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that its alfapump has won the ‘Best Technology’ Award at the European Mediscience Awards in […]
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed in the CTT meta-analyses ANN ARBOR, Mich., June 15, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today presented results from an analysis comparing […]
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
CAMZYOS is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the underlying source of obstructive HCM VALOR-HCM is the second Phase 3 trial in which CAMZYOS demonstrated significant improvement in symptoms of obstructive HCM June 15, 2023 08:23 PM Eastern Daylight Time PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced […]
Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease
Verve to Receive $60 Million in Combined Upfront Payment and Equity Investment; Additional Capital Positioned to Extend Verve’s Expected Cash Runway into 2026 Verve has Opt-in Rights to Co-fund and Share in Potential Margins of Products Resulting from the Collaboration BOSTON, June 15, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. […]
CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received the recommendation from the independent Data and Safety Monitoring Board […]
CardieX Selected for Medtech Innovator’s 2023 Accelerator Cohort
IRVIVE, Calif., June 14, 2023 /PRNewswire/ — Cardiovascular health technology company, CardieX Limited, is pleased to announce it has been selected as part of MedTech Innovator’s 2023 Accelerator Cohort. MedTech Innovator is recognized as the world’s largest accelerator of medical technology companies. More than 1,150 companies applied to participate in the 2023 Accelerator program […]
PECA Labs Achieves Successful First-In-Human Implant of the MASA Valve Pediatric Pulmonary Valved Conduit in U.S. Clinical Trial
Novel Polymeric Valve Aims to Reduce Re-operations and Re-interventions PITTSBURGH–(BUSINESS WIRE)–PECA Labs, a medical device company reimagining vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, today announced the successful first-in-human implant of the MASA Valve. Designed for pediatrics, the MASA Valve is a […]
StemBioSys Announces Launch of CELLvo™ Atrial Cardiomyocyte, a Technological Leap Forward in Cardiotoxicity Screening
Developed in collaboration with REPROCELL, CELLvo™ Atrial Cardiomyocyte delivers non-genetically modified human heart cells that are chamber specific and derived from iPS (stem) cells SAN ANTONIO, June 13, 2023 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) announced today the launch of CELLvo™ Atrial Cardiomyocyte, a “chamber specific” human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to […]
Avertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth Orlando
AdventHealth Orlando performs their first implant of Guardian™ System, revolutionizing cardiac care in Central Florida EATONTOWN, N.J. and ORLANDO, Fla., June 13, 2023 (GLOBE NEWSWIRE) — Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary […]



